Protara Therapeutics (NASDAQ:TARA) Stock Rating Reaffirmed by HC Wainwright

Protara Therapeutics (NASDAQ:TARA)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $23.00 target price on the stock.

Separately, Oppenheimer upped their price target on shares of Protara Therapeutics from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Monday, April 22nd.

Protara Therapeutics Stock Performance

NASDAQ TARA opened at $2.87 on Monday. Protara Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $5.24. The stock has a market cap of $32.80 million, a PE ratio of -0.77 and a beta of 1.80. The firm’s fifty day moving average price is $3.57 and its two-hundred day moving average price is $2.56.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.13. As a group, sell-side analysts predict that Protara Therapeutics will post -3.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Protara Therapeutics stock. Oppenheimer & Co. Inc. bought a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned 0.09% of Protara Therapeutics as of its most recent SEC filing. 38.13% of the stock is currently owned by hedge funds and other institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.